Fallowfield, Lesley

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine

Breast Cancer Treatment StudiesEstrogen and related hormone effects

Cited by 1,759

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 1,369

Ovarian cancer

Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 1,362

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet

Ovarian cancer diagnosis and treatmentGlobal Cancer Incidence and Screening

Cited by 1,048

Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial

Fallowfield, L., Jenkins, V., Farewell, V., Saul, J., Duffy, A., & Eves, R. (2002) · The Lancet

Patient-Provider Communication in HealthcareInnovations in Medical Education

Cited by 854

Information needs of patients with cancer: results from a large study in UK cancer centres

Jenkins, V, Fallowfield, L., & Saul, J. (2001) · British Journal of Cancer

Patient-Provider Communication in HealthcareHealth Literacy and Information Accessibility

Cited by 845

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Menon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet

Ovarian cancer diagnosis and treatmentGlobal Cancer Incidence and Screening

Cited by 730

Psychiatric morbidity and its recognition by doctors in patients with cancer

Fallowfield, L., Ratcliffe, D., Jenkins, V, & Saul, J. (2001) · British Journal of Cancer

Cancer survivorship and carePatient-Provider Communication in Healthcare

Cited by 694

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 540

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline

Di Maio, M., Basch, E., Denis, F., Fallowfield, L. J., Ganz, P. A., Howell, D., Kowalski, C., Perrone, F., Stover, A. M., Sundaresan, P., et al. (2022) · Annals of Oncology

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 509

Truth may hurt but deceit hurts more: communication in palliative care

Fallowfield, L. J., Jenkins, V. A., & Beveridge, H. A. (2002) · Palliative Medicine

Palliative Care and End-of-Life IssuesPatient-Provider Communication in Healthcare

Cited by 498

Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 485

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 338

Intentional and non-intentional non-adherence to medication amongst breast cancer patients

Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer

Medication Adherence and ComplianceCancer survivorship and care

Cited by 300

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Cella, D., & Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment

Breast Cancer Treatment StudiesCancer survivorship and care

Cited by 286

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 230

Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study

Menon, U., Gentry-Maharaj, A., Ryan, A., Sharma, A., Burnell, M., Hallett, R., Lewis, S., Lopez, A., Godfrey, K., Oram, D., et al. (2008) · BMJ

Ethics in Clinical ResearchHealth Policy Implementation Science

Cited by 151

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study

O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., et al. (2021) · European Journal of Cancer

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 83

Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study

Fallowfield, L., Osborne, S., Langridge, C., Monson, K., Kilkerr, J., & Jenkins, V. (2015) · The Breast

HER2/EGFR in Cancer ResearchHealth Systems, Economic Evaluations, Quality of Life

Cited by 34

Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits

Fallowfield, L. J., Catt, S. L., May, S. F., Matthews, L., Shilling, V. M., Simcock, R., Westwell, S., & Jenkins, V. A. (2017) · Supportive Care in Cancer

Patient-Provider Communication in HealthcarePalliative Care and End-of-Life Issues

Cited by 25